{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:22Z","timestamp":1787841022892,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein\u2013Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of ritux- imab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T10:09:47Z","timestamp":1589191787000},"page":"68-73","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Ofatumumab for Post-Transplant Lymphoproliferative Disorder"],"prefix":"10.4103","volume":"15","author":[{"given":"Madhav","family":"Seshadri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20241211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus- related post-transplant lymphoproliferative disease (EBV- PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R2-11-20241211","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-11-20241211","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R4-11-20241211","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"R5-11-20241211","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2008.150","article-title":"EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT","volume":"42","author":"Ocheni","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R6-11-20241211","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"R7-11-20241211","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-11-20241211","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428194.2018.1543877","article-title":"Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk","volume":"60","author":"Van Besien","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R9-11-20241211","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/14737140.2015.1028919","article-title":"Biosimilar monoclonal antibodies in lymphoma: a critical appraisal","volume":"15","author":"Rioufol","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"R10-11-20241211","doi-asserted-by":"crossref","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","article-title":"ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Rosell\u00f2","year":"2017","journal-title":"Ann Oncol"},{"key":"R11-11-20241211","doi-asserted-by":"crossref","first-page":"e26333","DOI":"10.4161\/onci.26333","article-title":"Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses","volume":"2","author":"Baldo","year":"2013","journal-title":"Oncoimmunology"},{"key":"R13-11-20241211","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"R14-11-20241211","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.4049\/jimmunol.1202588","article-title":"Comparative assessment of clinically utilized CD20- directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties","volume":"190","author":"Rafiq","year":"2013","journal-title":"J Immunol"},{"key":"R15-11-20241211","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3109\/10428194.2012.691484","article-title":"Transformed large B-cell lymphoma in rituximab- allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab","volume":"54","author":"Linden","year":"2013","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.04.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:38Z","timestamp":1787838038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.04.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.04.004","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}